Skip to main content

Table 5 Comparison of cellular factors levels between the groups positive and negative for HPV

From: Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer

Cellular Factors PCa group (a) vs control (b) HPV-positive samples (c) vs HPV-negative samples (d) HPV-positive PCa (e) vs HPV-negative PCa (f) HPV-positive control (g) vs HPV-negative control (h) P* P+ P$ P^
NF-κB a:19.4 ± 7.4
b:9.5 ± 7
c: 23.5 ± 5.8
d: 13.2 ± 7.9
e: 24.2 ± 6
f: 17 ± 7
g: 20 ± 3.9
h: 8 ± 6.05
< 0.0001 < 0.0001 0.00091.42 0.004
TNF-α a:17 ± 7.4
b:11.7 ± 6.7
c: 21.1 ± 6
d: 12.8 ± 6.6
e: 22.4 ± 6.4
f: 14.3 ± 6.4
g: 19.5 ± 3.1
h: 10.6 ± 6.3
0.002 < 0.0001 < 0.0001
1.56
0.03
IL-1 a:13 ± 5.7
b:7.8 ± 5.3
c: 17.2 ± 4.1
d: 9.1 ± 5.2
e: 17.3 ± 4.1
f: 10.9 ± 5.1
g: 16.7 ± 4.2
h: 6.5 ± 4.1
0.0002 < 0.0001 0.0003
1.57
0.002
IL-6 a:14.4 ± 6
b:8.9 ± 6.6
c: 18.9 ± 5
d: 10.2 ± 5.8
e: 18.9 ± 5.2
f: 12.2 ± 5.2
g: 19 ± 3.9
h: 7.5 ± 5.6
0.0004 < 0.0001 < 0.0001
2.51
0.0004
IL-8 a: 12.62 ± 6.2
b: 5.68 ± 5.1
c: 17.3 ± 5.1
d:7.6 ± 5.3
e: 17.7 ± 5.4
f: 10.1 ± 5.09
g: 15.5 ± 3.1
h: 4.2 ± 3.5
< 0.0001 < 0.0001 0.004
1.77
0.006
IL-11 a: 15.6 ± 8.3
b: 7.1 ± 6.2
c: 20.52 ± 6.8
d: 9.8 ± 7.4
e: 21.2 ± 7.2
f: 12.8 ± 7.4
g: 17 ± 5.08
h: 5.7 ± 4.1
< 0.0001 < 0.0001 0.02
1.6
ns
VEGF a: 38.64 ± 10.8
b: 13.7 ± 6.9
c: 48.5 ± 9.5
d: 25.8 ± 12.5
e: 52.58 ± 3.5
f: 35.8 ± 4.2
g: 29.5 ± 1.2
h: 11.9 ± 3.7
< 0.0001 < 0.0001 0.0009
1.46
0.005
TGF-β a: 15.2 ± 7.6
b: 7.5 ± 5.1
c: 19.2 ± 5.7
d: 10.1 ± 7
e: 19.9 ± 6.1
f: 12.9 ± 7.2
g: 16 ± 1.6
h: 6.2 ± 4.2
< 0.0001 < 0.0001 0.02
1.54
ns
Rb a: 9.1 ± 5.7
b: 14.06 ± 6.4
c: 2.4 ± 1.08
d: 13.8 ± 4.6
e: 2.6 ± 1.01
f: 12.3 ± 4.1
g: 1.5 ± 1
h: 15.8 ± 4.6
0.0006 < 0.0001 < 0.0001 0.0003
P53 a: 10.4 ± 6.7
b: 13.9 ± 6.6
c: 3 ± 1.3
d:14.7 ± 5.2
e: 3.2 ± 1.35
f: 14.03 ± 5.2
g: 2 ± 0.8
h: 15.68 ± 5.09
0.04 < 0.0001 < 0.0001 0.002
ROS a: 10.2 ± 9.7
b: 6.09 ± 5.3
c: 22.3 ± 5.7
d: 3.7 ± 2.7
e: 23.4 ± 5.5
f: 3.1 ± 2.04
g: 17 ± 3.6
h: 4.5 ± 3.3
0.03 < 0.0001 < 0.0001
7.5
ns
RNS a: 11.8 ± 10.3
b: 5.2 ± 5.3
c: 19.7 ± 8.9
d: 5.9 ± 6.5
e: 20.2 ± 9.7
f: 7.7 ± 7.8
g: 17.2 ± 2.6
h: 3.5 ± 2.8
0.0002 < 0.0001 0.0004
2.6
0.003
Survivin a: 17.8 ± 4.8
b: 9 ± 6.2
c: 22 ± 3.2
d: 12.1 ± 5.8
e: 21.9 ± 3.2
f: 15.8 ± 4.1
g: 22.7 ± 3.5
h: 7.03 ± 3.2
< 0.0001 < 0.0001 0.0006 < 0.0001
Bcl-2 a: 12.1 ± 4.2
b: 6.4 ± 4.5
c: 15.9 ± 3.4
d: 8.1 ± 3.9
e: 15.6 ± 3.7
f: 10.4 ± 3.4
g: 17.3 ± 0.8
h: 4.9 ± 1.9
0/0001 < 0.0001 0.002 < 0.0001
CD44 a: 7.9 ± 5.1
b: 4.03 ± 2.4
c: 7.8 ± 5.1
d: 6.1 ± 4.5
e:7.9 ± 5.4
f: 8 ± 5.01
g: 7.5 ± 3.8
h: 3.5 ± 1.8
0.0003 ns ns ns
TWIST a: 10.2 ± 12.2
b: 6.4 ± 7.2
c: 25.7 ± 7.5
d: 3.1 ± 2.6
e: 26.2 ± 8.1
f: 2.4 ± 1.3
g: 23 ± 1.6
h: 4.03 ± 3.5
ns < 0.0001 < 0.0001 ns
E-cad a: 12.9 ± 8.4
b: 13.5 ± 5.6
c: 3.4 ± 2.08
d: 16.5 ± 5.6
e: 3.5 ± 2.2
f:17.5 ± 6.2
g: 3 ± 0.8
h: 15.07 ± 4.2
ns < 0.0001 < 0.0001 < 0.0001
N-cad a: 10.7 ± 11.6
b: 5.8 ± 8.4
c: 25.8 ± 7.6
d:3.2 ± 2.4
e: 25.7 ± 8.09
f: 3.4 ± 2.1
g: 26.2 ± 6.2
h: 2.9 ± 2.7
0.009 < 0.0001 < 0.0001 0.004
PTPN13 a: 9.7 ± 5.9
b: 12.9 ± 6.6
c: 4.4 ± 5.6
d: 13.1 ± 5
e: 5 ± 6.01
f:12.08 ± 4.4
g: 2 ± 0.8
h: 14.5 ± 5.5
0.03 < 0.0001 0.0007 0.004
SLUG a: 2.1 ± 1.8
b: 1.1 ± 2.7
c: 3.8 ± 1.4
d: 1.01 ± 1.9
e: 3.9 ± 1.4
f: 1.2 ± 1.3
g: 3.4 ± 1.2
h: 0.6 ± 2.6
ns < 0.0001 < 0.0001 Ns
  1. Geometric Mean ± Standard Deviation, *: comparison between group a versus group b, +: comparison between group c versus group d, $: comparison between group e versus group f, ^: $: comparison between group g versus group h, FDR correction for multiple comparisons by Benjamini-Hochberg method